Cuprina Provides Update on Research Studies with Three Leading Education Institutes
Cuprina Holdings (Nasdaq: CUPR) has provided updates on three one-year research studies with leading educational institutes focused on developing collagen peptide molecules from American bullfrog skin. The company has made significant progress in these collaborations:
With Republic Polytechnic, Cuprina identified methods to generate peptides for cosmeceutical applications. The collaboration with the Institute for Health Innovation and Technology at NUS is exploring bullfrog collagen peptides for 3D printable wound care dressings, including microneedling patches. The partnership with the Singapore Institute of Technology aims to produce superior powdered bullfrog collagen peptides.
Research has shown that bullfrog-derived collagen achieved 90% wound closure in 24 hours compared to 34% for bovine collagen. The global collagen peptides market is projected to grow from $699 million in 2023 to $922 million in 2028, at a CAGR of 5.7%.
Cuprina Holdings (Nasdaq: CUPR) ha fornito aggiornamenti su tre studi di ricerca annuali condotti con importanti istituti educativi, focalizzati sullo sviluppo di molecole di peptidi di collagene derivati dalla pelle di rana toro americana. L'azienda ha raggiunto progressi significativi in queste collaborazioni:
Con il Republic Polytechnic, Cuprina ha individuato metodi per generare peptidi destinati ad applicazioni cosmeceutiche. La collaborazione con l'Institute for Health Innovation and Technology della NUS sta esplorando l'uso di peptidi di collagene di rana toro per medicazioni per ferite stampabili in 3D, inclusi cerotti per microneedling. La partnership con il Singapore Institute of Technology mira a produrre peptidi di collagene in polvere superiori, derivati dalla rana toro.
La ricerca ha dimostrato che il collagene derivato dalla rana toro ha raggiunto una chiusura della ferita del 90% in 24 ore, rispetto al 34% del collagene bovino. Il mercato globale dei peptidi di collagene è previsto crescere da 699 milioni di dollari nel 2023 a 922 milioni di dollari nel 2028, con un tasso di crescita annuo composto (CAGR) del 5,7%.
Cuprina Holdings (Nasdaq: CUPR) ha proporcionado actualizaciones sobre tres estudios de investigación de un año con importantes institutos educativos, enfocados en el desarrollo de moléculas de péptidos de colágeno a partir de la piel de rana toro americana. La compañía ha logrado avances significativos en estas colaboraciones:
Con el Republic Polytechnic, Cuprina identificó métodos para generar péptidos para aplicaciones cosmeceúticas. La colaboración con el Institute for Health Innovation and Technology de NUS está explorando péptidos de colágeno de rana toro para apósitos para heridas imprimibles en 3D, incluidos parches de microneedling. La asociación con el Singapore Institute of Technology busca producir péptidos de colágeno en polvo superiores derivados de rana toro.
La investigación ha demostrado que el colágeno derivado de rana toro logró un 90% de cierre de heridas en 24 horas en comparación con el 34% del colágeno bovino. Se proyecta que el mercado global de péptidos de colágeno crezca de
Cuprina Holdings (나스닥: CUPR)는 미국 황소개구리 피부에서 추출한 콜라겐 펩타이드 분자 개발에 중점을 둔 1년 연구 3건에 대해 주요 교육 기관과의 협력 현황을 업데이트했습니다. 회사는 이 협력에서 상당한 진전을 이루었습니다:
Republic Polytechnic과 함께 Cuprina는 코스메슈티컬 응용을 위한 펩타이드 생성 방법을 확인했습니다. NUS의 Institute for Health Innovation and Technology와의 협력은 3D 프린팅 가능한 상처 치료 드레싱(마이크로니들링 패치 포함)을 위한 황소개구리 콜라겐 펩타이드를 연구 중입니다. Singapore Institute of Technology와의 파트너십은 우수한 분말 형태의 황소개구리 콜라겐 펩타이드 생산을 목표로 합니다.
연구 결과, 황소개구리 유래 콜라겐은 24시간 내에 90% 상처 치유율을 달성했으며, 이는 소 콜라겐의 34%와 비교됩니다. 글로벌 콜라겐 펩타이드 시장은 2023년 6억 9,900만 달러에서 2028년 9억 2,200만 달러로 연평균 성장률(CAGR) 5.7%로 성장할 것으로 예상됩니다.
Cuprina Holdings (Nasdaq : CUPR) a fourni des mises à jour sur trois études de recherche d'un an menées avec des instituts éducatifs de premier plan, axées sur le développement de molécules de peptides de collagène à partir de la peau de grenouille taureau américaine. L'entreprise a réalisé des progrès significatifs dans ces collaborations :
Avec le Republic Polytechnic, Cuprina a identifié des méthodes pour générer des peptides destinés à des applications cosmétosanitaires. La collaboration avec l'Institute for Health Innovation and Technology de la NUS explore les peptides de collagène de grenouille taureau pour des pansements de soins des plaies imprimables en 3D, y compris des patchs de microneedling. Le partenariat avec le Singapore Institute of Technology vise à produire des peptides de collagène en poudre de qualité supérieure issus de la grenouille taureau.
Les recherches ont montré que le collagène dérivé de la grenouille taureau obtenait une fermeture de plaie de 90 % en 24 heures, contre 34 % pour le collagène bovin. Le marché mondial des peptides de collagène devrait passer de 699 millions de dollars en 2023 à 922 millions de dollars en 2028, avec un taux de croissance annuel composé (CAGR) de 5,7 %.
Cuprina Holdings (Nasdaq: CUPR) hat Updates zu drei einjährigen Forschungsstudien mit führenden Bildungseinrichtungen bereitgestellt, die sich auf die Entwicklung von Kollagenpeptidmolekülen aus der Haut des amerikanischen Ochsenfrosches konzentrieren. Das Unternehmen hat in diesen Kooperationen bedeutende Fortschritte erzielt:
Mit dem Republic Polytechnic identifizierte Cuprina Methoden zur Herstellung von Peptiden für kosmetisch-medizinische Anwendungen. Die Zusammenarbeit mit dem Institute for Health Innovation and Technology der NUS erforscht Kollagenpeptide des Ochsenfrosches für 3D-druckbare Wundauflagen, einschließlich Mikronadelpflaster. Die Partnerschaft mit dem Singapore Institute of Technology zielt darauf ab, hochwertige pulverisierte Kollagenpeptide aus Ochsenfrosch herzustellen.
Forschungen zeigten, dass Kollagen aus Ochsenfrosch eine 90%ige Wundverschlussrate innerhalb von 24 Stunden erreichte, verglichen mit 34% bei Rinderkollagen. Der globale Markt für Kollagenpeptide wird prognostiziert, von 699 Millionen USD im Jahr 2023 auf 922 Millionen USD im Jahr 2028 zu wachsen, mit einer jährlichen Wachstumsrate (CAGR) von 5,7%.
- Demonstrated superior wound healing with 90% closure in 24 hours vs 34% for bovine collagen
- Identified viable method for generating peptides for cosmeceutical applications
- Research supported by National Additive Manufacturing Innovation Cluster Singapore
- Global collagen peptides market expected to reach $922M by 2028, growing at 5.7% CAGR
- Bullfrog collagen shows superior biocompatibility and thermal stability compared to other sources
- None.
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed at helping Cuprina and these institutes jointly produce collagen peptide molecules derived from American bullfrog skin. These peptides, as well as their short chain variants, are widely considered to be useful in the manufacture of an array of medical, pharmaceutical, nutraceutical and cosmetic products.
The first study was performed pursuant to a consultancy proposal (“CP”) signed in February 2024 with Republic Polytechnic (“RP”), an institute of higher learning under the purview of the Ministry of Education in Singapore. Under this agreement, Cuprina and RP collaborated to generate bullfrog collagen peptides that can be sold as is or separated and sold as individual peptide fragments.
Since the completion of this consultancy proposal in February 2025, Cuprina has identified a method to generate a series of these peptides that can potentially be used for cosmeceutical applications including skin moisturization, collagen remodeling, and other commercial applications. Cuprina is currently in the process of pursuing marketing opportunities for these peptides with a number of cosmeceutical entities.
Cuprina’s second study, a research collaboration agreement (“RCA”) which commenced in October 2024, was signed with the Institute for Health Innovation and Technology at the National University of Singapore, Singapore’s flagship university that offers a global approach to education, research and entrepreneurship. Joint research from this agreement is aimed at exploring the viability of using bullfrog collagen peptides in the production of 3D printable wound care dressings for a variety of research and clinical applications. Funding for this research is supported by the National Additive Manufacturing Innovation Cluster Singapore, a national platform hosted by the Agency for Science, Technology and Research.
Currently, Cuprina is performing testing aimed at measuring the effect of integrating bullfrog collagen into the structure of microneedling patches, which contain tiny needles that allow active ingredients to penetrate deeper into the skin and enhance wound healing. If these tests prove successful, these new patches could help to control the inflammation that typically impedes wound healing.
The third study is an RCA with the Singapore Institute of Technology, an autonomous university in Singapore, that commenced in January 2025. Both parties endeavor to produce a superior powdered form of bullfrog collagen peptides that can be sold as is or as individual peptide fragments suitable for cosmeceuticals.
In vivo and in vitro tests have demonstrated that bullfrog skins generate a pristine, triple helix collagen molecule that possesses numerous beneficial properties including superior biocompatibility and thermal stability compared to bovine and other collagen sources. In addition, published studies have reported that bullfrog-derived collagen produced 90 percent wound closure in 24 hours versus 34 percent for bovine collagen.
“We are very gratified by our collaborations with these three leading research institutes,” said Cuprina Chief Executive Officer David Quek. “I am optimistic that our joint efforts will lead to additional productive commercial applications for bullfrog-derived collagen peptides. Given the demonstrated advantages of bullfrog collagen, we believe this market has significant potential for worldwide growth.”
According to research firm MarketsandMarkets.com, the global collagen peptides market is expected to grow from US
About Cuprina Holdings (Cayman) Limited
Cuprina is a Singapore-based biomedical and biotechnology company dedicated to the development and commercialization of innovative products for the management of chronic wounds and infertility, as well as operating in the health and beauty sectors. The Company’s expertise in biomedical research allows it to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://www.cuprina.com.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
1MarketsandMarkets Research Private Ltd (2023). Collagen Peptides Market by Source (Bovine, Porcine, Marine & Poultry), Application (Food & Beverages, Nutritional Products, Cosmetics & Personal Care Products, Pharmaceuticals), Form (Dry, Liquid) and Region - Global Forecast to 2028.
FAQ
What are the key findings from Cuprina's (CUPR) bullfrog collagen research?
Which institutions is Cuprina (CUPR) collaborating with for collagen research?
What is the market potential for Cuprina's (CUPR) collagen peptides products?
What applications is Cuprina (CUPR) developing for its bullfrog collagen?
How does Cuprina's (CUPR) bullfrog collagen compare to traditional sources?
